Leerink Swann Reiterates Market Perform Rating for Trillium Therapeutics (TR)

Trillium Therapeutics (TSE:TR) (NASDAQ:TRIL)‘s stock had its “market perform” rating reissued by analysts at Leerink Swann in a report issued on Friday.

TR opened at C$30.20 on Friday. Trillium Therapeutics has a 12-month low of C$28.50 and a 12-month high of C$39.45.

How to Become a New Pot Stock Millionaire

Trillium Therapeutics (TSE:TR) (NASDAQ:TRIL) last posted its quarterly earnings data on Friday, March 9th. The company reported C($0.91) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of C($1.06) by C$0.15.

TRADEMARK VIOLATION WARNING: “Leerink Swann Reiterates Market Perform Rating for Trillium Therapeutics (TR)” was first reported by Week Herald and is the sole property of of Week Herald. If you are viewing this story on another site, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The legal version of this story can be viewed at https://weekherald.com/2018/04/17/leerink-swann-reiterates-market-perform-rating-for-trillium-therapeutics-tr.html.

Trillium Therapeutics Company Profile

Trillium Therapeutics Inc is a Canada-based clinical stage immuno-oncology company developing therapies for the treatment of cancer. The Company leads program, TTI-621, which is a SIRPaFc fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1).

Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply